Axxam and Polyphor bag EU funding for discovery of new GLP-1R modulators
Milan/Allschill – Italian Axxam SpA and Swiss Polyphor Ltd have joined forces to develop new APIs for treatment of diabetes II. Within the Eurostars programme the companies will receive an EUR 3.1 million EU fund over the next 3 years for combining their platforms to find modulators of the Glucagon-like-peptide 1 receptor (GLP-1R). Activated GLP1R stimulates the adenylyl cyclase pathway which results in increased insulin synthesis and release of insulin. Consequently GLP1R has been suggested as a potential target for the treatment of diabetes.GLP1R is also expressed in the brain where it is involved in the control of appetite. While Axxam will provide tools and assays for drug screening, Polyphor will generate scaffolds that interact with the target, including allosteric modulators and receptor desensitizers. The Swiss firm has build expertise to design small cyclic peptide-like molecules that mimic secondary structure motifs involved in protein-protein interactions (PEMfinder platform) and will bring in its MacroFinder® compound library into the partnership. Axxam performs a wide range of activities including assay development, high-throughput screening, compound profiling and hit-to-lead testing.